Drug Profile
Mecasermin rinfabate - Oak Hill Bio/ Takeda
Alternative Names: HGT-ROP-001; IGF-I/IGFBP-3; Insulin-like growth factor-I/insulin-like growth factor binding protein-3; IPLEX; Mecasermin rinfabate; OHB-607; Premiplex; rhIGF-I/rhIGFBP-3; SHP607; SomatoKine; Somatomedin-C/Somatomedin-1-binding-protein-3; TAK 607Latest Information Update: 11 Jan 2024
Price :
$50
*
At a glance
- Originator Insmed
- Developer Insmed; Oak Hill Bio; Takeda
- Class Antihyperglycaemics; Eye disorder therapies; Growth factors; Osteoporosis therapies; Recombinant proteins
- Mechanism of Action Insulin like growth factor binding protein 3 stimulants; Insulin-like growth factor I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bronchopulmonary dysplasia; Lung disorders
- Market Withdrawal Growth disorders
- Suspended Muscular dystrophies
- No development reported Amyotrophic lateral sclerosis; Retinopathy of prematurity
- Discontinued Burns; Fracture; Insulin resistance; Lipodystrophy; Postmenopausal osteoporosis; Short stature; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 10 Jan 2024 Chiesi Group entered into research and development agreement with Oak Hill for the development of OHB-607
- 09 Jan 2024 Chiesi Group and Oak Hillplans plans to re-initiate phase IIb trial for Bronchopulmonary dysplasia in the United States, Europe, and Japan in 2024
- 25 May 2022 Oak Hill Bio plans a phase IIb study of Mecasermin rinfabate in year 2022